Lipid profile in hospitalized patients with COVID-19 depending on the outcome of its acute phase: data from the international registry "Dynamics analysis of comorbidities in SARS-CoV-2 infection survivors"

Abstract

Aim. To study the lipid profile in hospitalized patients with coronavirus disease 2019 (COVID-19) depending on the outcome of its acute phase according to the AKTIV international registry.Material and methods. The AKTIV registry included men and women over 18 years of age with a diagnosis of COVID-19, who were treated in a hospital. A total of 9364 patients were included in the registry, of which 623 patients were analyzed for levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C) and triglycerides on days 1-2 of hospitalization. The level of high-density lipoprotein cholesterol (HDL-C) was calculated using the Friedewald equation.Results. We found that a decrease in LDL-C level was significantly associated with an unfavorable prognosis for hospitalized patients with COVID-19. This pattern persisted in both univariate and multivariate analyses. LDL-C levels in the final multivariate model had a significant relationship with the prognosis (an increase in the death risk by 1,7 times with a decrease per 1 mmol/l). In addition, we found that the survival of patients with an indicator level of <2,45 mmol/l is significantly worse than in patients with an LDL-C level ≥2,45 mmol/l. All patients with high LDL-C ((≥4,9 mmol/l) survived, while among patients with low LDL-C (<2,45 mmol/l. All patients with high LDL-C ((≥4,9 mmol/l) survived, while among patients with low LDL-C (<1,4 mmol/l), mortality was 13,04%, which was significantly higher than in patients with LDL-C ≥1,4 mmol/l (6,32%, p=0,047).Conclusion. A decrease in LDL-C in the acute period is significantly associated with an unfavorable prognosis for hospitalized patients with COVID-19. Determination of LDL-C can be included in the examination program for patients with COVID-19. However, the predictive value of this parameter requires further study in prospective clinical studies.

Body mass index as a predictor of the severity of coronavirus infection in patients with cardiovascular pathology

“…В работе проведен анализ коморбидной патологии, в результате которого было установлено, что у групп больных с тяжелым течением и неблагоприятным исходом инфекция COVID-19 протекала на фоне хронической сердечной недостаточности, ОНМК, фибрилляции предсердий и СД 2 типа чаще, чем у пациентов с благоприятным течением болезни, эти результаты согласуются с данными международного регистра АКТИВ SARS-CoV-2 [4].…”

“…Однако с возникновением эпидемий азиатского и гонконгского гриппа в прошлом веке, а также пандемии COVID-19, ожирение стало рассматриваться как фактор риска и инфекционных болезней. Согласно данным из международного регистра АКТИВ, созданного в Евразийском регионе для оценки влияния полиморбидности пациентов на развитие тяжелого течения новой коронавирусной инфекции, ожирение являлось второй по частоте встречаемости коморбидной патологией, им страдало 35% пациентов, включенных в исследование [4].…”